December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Clene Inc. - Common Stock (NQ:CLNN)

5.325 +0.135 (+2.60%)
Streaming Delayed Price Updated: 11:17 AM EST, Jan 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Clene Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Clene Inc. (NASDAQ: CLNN) to Discuss Lead Candidate CNM-Au8(R) Biomarker, Clinical Data for ALS with Food and Drug Administration Leadership
Via Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Announces Upcoming In-Person FDA Meeting to Discuss CNM-Au8
Via Investor Brand Network
Does Multiple Sclerosis Reduce Risk of Developing Dementia?
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Management Presenting Recent Achievements, CNM-Au8(R) Results, at H.C. Wainwright Conference
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Seeks to Transform Neurodegenerative Disorder Treatments, with Rise in Prevalence and Associated Markets
Via Investor Brand Network
Researchers Identify New Gene Behind ALS Onset
Via Investor Brand Network
News headline image
Why Argan Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Management to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Via Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Positioned as Leader in Addressing Neurodegenerative Diseases
Via Investor Brand Network
Topics Intellectual Property
Clene Inc.’s (NASDAQ: CLNN) CEO Discusses Company’s Mission, CNM-Au8(R) Trial Results, and Future Plans on BioMedWire Podcast
Via Investor Brand Network
Clene Inc.’s (NASDAQ: CLNN) CNM-Au8(R) Affects Key Biomarkers and Long-term Survival in ALS Trials
Via Investor Brand Network
UCSF Team Tests New Drug That Could Reverse Multiple Sclerosis
Via Investor Brand Network
Antioxidants in Seaweed Could Help in Forestalling Parkinson’s Disease
Via Investor Brand Network
Clene Inc.’s (NASDAQ: CLNN) Makes Significant Strides in Developing its Lead Agent, CNM-Au8(R), to Address Neurodegenerative Conditions
Via Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) CEO Spotlighted in Recent BioMedWire Podcast Episode
Via Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Releases Q2 2024 Financial Results, Provides Updates
Via Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Submits New CNM-Au8 Biomarker, Clinical Efficacy Data to FDA
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Advances Neurodegenerative Disease Treatment with Innovative Nanotherapeutics
Via Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Announces Participation in Upcoming Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Discusses Important Developments of CNM-Au8(R) and Its Novel Technology During Xtalks Podcast
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Presents Updates on CNM-Au8(R) at Emerging Growth Conference 73 – Biotech Feature
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Announces Plan to Submit Briefing Book to FDA Preceding Type C Interaction
Via Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Present at the 73rd Emerging Growth Conference
Via Investor Brand Network
Study Suggests Vitamin B Deficiency Could Be Pivotal in Parkinson’s Disease
Via Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Management Slated to Participate in Upcoming Emerging Growth Conference
Via Investor Brand Network
News headline image
Gold Rises Sharply; Methode Electronics Shares Spike Higher ↗
 
Via Benzinga
News headline image
Why ConAgra Brands Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
 
Via Benzinga
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Prepares to Submit Briefing Book to FDA, Looks to Obtain Key Feedback Regarding NDA for CNM-Au8 in ALS
Via Investor Brand Network
News headline image
Nasdaq Dips Over 300 Points; PepsiCo Reports Weak Sales ↗
 
Via Benzinga
News headline image
S&P 500 Edges Higher; Indivior Shares Plummet ↗
 
Via Benzinga
Topics Stocks
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.